QuidelOrtho Corporation (QDEL)
Chart Events
Performance Outlook
| Previous Close | 71.63 |
| Open | 71.14 |
| Bid | 71.53 x 800 |
| Ask | 71.63 x 800 |
| Day's Range | 70.83 - 72.08 |
| 52 Week Range | 66.88 - 102.00 |
| Volume | |
| Avg. Volume | 519,836 |
| Market Cap | 4.778B |
| Beta (5Y Monthly) | 0.27 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.02 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 118.14 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for QDEL
Related Research
- QuidelOrtho CorporationQDEL: Raising target price to $68.00QUIDELORTHO CORP has an Investment Rating of SELL; a target price of $68.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.RatingFair ValueEconomic Moat5 days agoArgus Research
Business WireQuidelOrtho Receives CLIA Waiver for Sofia® 2 SARS Antigen+ FIA
SAN DIEGO, September 21, 2023--QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has been granted CLIA Waiver from the U.S. Food and Drug Administration (FDA), applying to its new Sofia® 2 SARS Antigen+ FIA. The Sofia 2 SARS Antigen+ FIA is the first rapid antigen test that detects COVID-19 to be awarded FDA market clearance t
Insider MonkeyShould You Add QuidelOrtho (QDEL) to Your Portfolio?
ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Value Strategy” second quarter 2023 investor letter. A copy of the same can be downloaded here. The strategy outperformed the Russell 2000 value Index in the second quarter. On an absolute basis, the strategy gained all 11 sectors it invested in during the quarter. IT […]
Business WireQuidelOrtho to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
SAN DIEGO, August 28, 2023--QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Morgan Stanley 21st Annual Global Healthcare Conference in New York on September 12, 2023.
